GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Annexin Pharmaceuticals AB (publ) ANNX.ST · SEK

Health Care · Nasdaq Stockholm · 🇸🇪 Sweden

Compare

9.44

+6.07%

Close of 9 Nov 2026, in SEK

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in SEK, from our data supplier.

FY2025

Net income

−SEK 36.9m

FY2016FY2025

Free cash flow

−SEK 37.1m

FY2016FY2025

Shareholders' equity

SEK 24.9m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Gross profit−SEK 48,000−SEK 193,000−SEK 193,000−SEK 193,000−SEK 192,000−SEK 193,000−SEK 193,000−SEK 193,000−SEK 477,000−SEK 75,362
Research and developmentSEK 26.2mSEK 40.8mSEK 36.0mSEK 28.4mSEK 42.1mSEK 33.6mSEK 21.4mSEK 20.4mSEK 24.1mSEK 9.2m
Operating income−SEK 36.3m−SEK 50.5m−SEK 44.2m−SEK 40.7m−SEK 50.5m−SEK 43.7m−SEK 28.3m−SEK 28.7m−SEK 30.9m−SEK 9.8m
Net income−SEK 36.9m−SEK 50.3m−SEK 44.1m−SEK 40.7m−SEK 52.1m−SEK 44.7m−SEK 28.4m−SEK 28.8m−SEK 30.9m−SEK 9.8m
Diluted earnings per share-0.05-0.12-0.13-0.16-0.38-0.56-0.95-0.96-3.08-5.92

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsSEK 30.2mSEK 19.0mSEK 26.8mSEK 36.7mSEK 52.8mSEK 25.2mSEK 16.0mSEK 46.0mSEK 30.8mSEK 23.5m
Cash and short-term investmentsSEK 27.4mSEK 16.3mSEK 21.4mSEK 31.1mSEK 49.5mSEK 18.1mSEK 4.3mSEK 30.2mSEK 14.8mSEK 14.4m
Total liabilitiesSEK 5.2mSEK 5.3mSEK 7.9mSEK 6.5mSEK 6.1mSEK 4.5mSEK 4.5mSEK 6.2mSEK 6.4mSEK 7.9m
Debt——————SEK 227,000SEK 479,000SEK 729,000SEK 979,170
Shareholders' equitySEK 24.9mSEK 13.7mSEK 18.8mSEK 30.2mSEK 46.7mSEK 20.6mSEK 11.5mSEK 39.9mSEK 24.4mSEK 15.6m
Shares outstanding706m422m347m255m137m80m30m30m10m2m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−SEK 36.9m−SEK 50.2m−SEK 43.4m−SEK 41.2m−SEK 45.0m−SEK 39.2m−SEK 25.7m−SEK 28.5m−SEK 39.1m−SEK 9.9m
Capital spending−SEK 129,000—−SEK 43.4m————−SEK 50,000−SEK 149,000—
Free cash flow−SEK 37.1m−SEK 50.2m−SEK 86.8m−SEK 41.2m−SEK 45.0m−SEK 39.2m−SEK 25.7m−SEK 28.6m−SEK 39.2m−SEK 9.9m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Gross profit—−SEK 48,000———−SEK 48,000−SEK 145,000—
Operating income−SEK 11.4m−SEK 10.6m−SEK 10.3m−SEK 10.1m−SEK 8.6m−SEK 8.0m−SEK 12.6m−SEK 10.9m
Net income−SEK 11.6m−SEK 10.5m−SEK 10.5m−SEK 9.9m−SEK 8.5m−SEK 8.0m−SEK 12.3m−SEK 10.9m
Diluted earnings per share-1.64-1.49-0.01-0.01-0.01-0.01-0.03-0.03
Cash from operations−SEK 11.0m−SEK 10.0m−SEK 9.0m−SEK 9.0m—−SEK 8.0m−SEK 10.0m−SEK 11.0m
Total assetsSEK 8.0mSEK 20.0mSEK 30.2mSEK 39.5mSEK 49.1mSEK 48.0mSEK 19.0mSEK 28.6m
Cash and short-term investmentsSEK 5.3mSEK 17.1mSEK 27.4mSEK 36.9mSEK 46.3mSEK 45.2mSEK 16.3mSEK 25.6m
Shareholders' equitySEK 2.5mSEK 14.4mSEK 24.9mSEK 35.4mSEK 45.3mSEK 42.9mSEK 13.7mSEK 25.1m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-3.7%-3.7%21.9%
Net income-3.2%-3.8%22.1%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings-378.7-354.7-186.9-197.6-83.2-88.5-34.7-33.0-21.1

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 100-to-1 reverse split · 28 May 2025

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.